Correction to AstraZeneca Gives Rejected Drugs a Second Life Story
March 13 2017 - 11:06AM
Dow Jones News
AstraZeneca spends a few million dollars a year on its Emerging
Innovations Unit, with other research funding coming from outside
sources. "AstraZeneca Gives Rejected Drugs a Second Life," at 1100
GMT, incorrectly stated that the company spent tens of millions of
dollars a year on the unit in the 14th paragraph. Also, AstraZeneca
shelved a schizophrenia drug candidate because it didn't work in
schizophrenia. An earlier version of this article incorrectly
stated it was shelved because of its hormonal side effects in the
17th paragraph.
(END) Dow Jones Newswires
March 13, 2017 10:51 ET (14:51 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024